Potential use of selective and nonselective pim kinase inhibitors for cancer therapy

Journal of Medicinal Chemistry

Volumn 55, Issue 19, 2012, Pages 8199-8208

  Drygin, Denis ^a   Haddach, Mustapha ^b   Pierre, Fabrice ^c   Ryckman, David M ^a  

^a Cylene Pharmaceuticals   (United States)

^b HTK Corporation   (United States)

^c Apt 40 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (3 CHLOROPHENYLAMINO)BENZO [C][2,6]NAPHTHYRIDINE 8 CARBOXYLIC ACID; 5 CHLORO 3 [[5 [3 (4 METHYL 1,4 DIAZEPANE 1 CARBONYL) PHENYL]FURAN 2 YL]METHYLENE]INDOLIN 2 ONE; 7 (4H 1,2,4 TRIAZOL 3 YL)BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; CX 4945; CX 6258; N [(1 METHYLPIPERIDIN 4 YL)METHYL] 3 [3(TRIFLUOROMETHOXY)PHENYL]IMIDAZO[1,2 B]PYRIDAZIN 6 AMINE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PIM KINASE; PIM KINASE INHIBITOR; SGI 1776; SUNITINIB; UNCLASSIFIED DRUG;

DRUG MECHANISM; HUMAN; LEUKEMIA; NONHUMAN; PROSTATE CANCER; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; ISOENZYMES; NEOPLASMS; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-PIM-1; SIGNAL TRANSDUCTION;

EID: 84867390193     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3009234     Document Type: Review

References (70)

1. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 2001, 344 (14) 1031-1037
2. Orlowski, R. Z.; Stinchcombe, T. E.; Mitchell, B. S.; Shea, T. C.; Baldwin, A. S.; Stahl, S.; Adams, J.; Esseltine, D. L.; Elliott, P. J.; Pien, C. S.; Guerciolini, R.; Anderson, J. K.; Depcik-Smith, N. D.; Bhagat, R.; Lehman, M. J.; Novick, S. C.; O'Connor, O. A.; Soignet, S. L. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J. Clin. Oncol. 2002, 20 (22) 4420-4427
3. Shaheen, P. E.; Rini, B. I.; Bukowski, R. M. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports Clin. Genitourin. Cancer 2006, 5, 78-81
4. Jackson, L. J.; Pheneger, J. A.; Pheneger, T. J.; Davis, G.; Wright, A. D.; Robinson, J. E.; Allen, S.; Munson, M. C.; Carter, L. L. The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease Cell. Immunol. 2012, 272, 200-213
5. Shin, Y. S.; Takeda, K.; Shiraishi, Y.; Jia, Y.; Wang, M.; Jackson, L.; Wright, A. D.; Carter, L.; Robinson, J.; Hicken, E.; Gelfand, E. W. Inhibition of Pim1 kinase activation attenuates allergen-induced airway hyperresponsiveness and inflammation Am. J. Respir. Cell Mol. Biol. 2012, 46, 488-497
6. Cuypers, H. T.; Selten, G.; Quint, W.; Zijlstra, M.; Maandag, E. R.; Boelens, W.; van Wezenbeek, P.; Melief, C.; Berns, A. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region Cell 1984, 37, 141-150
7. Nawijn, M. C.; Alendar, A.; Berns, A. For better or for worse: the role of Pim oncogenes in tumorigenesis Nat. Rev. Cancer 2011, 11, 23-34
8. Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects with Relapsed/Refractory Leukemias. http://clinicaltrials.gov/ct2/show/NCT01239108.
9. Safety and Tolerability of AZD1208 and the Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients. http://clinicaltrials. gov/ct2/show/NCT01489722.
10. Brault, L.; Gasser, C.; Bracher, F.; Huber, K.; Knapp, S.; Schwaller, J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers Haematologica 2010, 95, 1004-1015
11. Mizuno, K.; Shirogane, T.; Shinohara, A.; Iwamatsu, A.; Hibi, M.; Hirano, T. Regulation of Pim-1 by Hsp90 Biochem. Biophys. Res. Commun. 2001, 281, 663-669
12. Xiao, K.; Liu, W.; Qu, S.; Sun, H.; Tang, J. Study of heat shock protein HSP90 alpha, HSP70, HSP27 mRNA expression in human acute leukemia cells J. Tongji Med. Univ. 1996, 16 (4) 212-216
13. Forshell, L. P.; Li, Y.; Forshell, T. Z.; Rudelius, M.; Nilsson, L.; Keller, U.; Nilsson, J. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas Oncotarget 2011, 2, 448-460
14. Mikkers, H.; Allen, J.; Knipscheer, P.; Romeijn, L.; Hart, A.; Vink, E.; Berns, A. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer Nat. Genet. 2002, 32, 153-159
15. Bullock, A. N.; Debreczeni, J.; Amos, A. L.; Knapp, S.; Turk, B. E. Structure and substrate specificity of the Pim-1 kinase J. Biol. Chem. 2005, 280, 41675-41682
16. Amaravadi, R.; Thompson, C. B. The survival kinases Akt and Pim as potential pharmacological targets J. Clin. Invest. 2005, 115 (10) 2618-2624
17. Tamburini, J.; Green, A. S.; Bardet, V.; Chapuis, N.; Park, S.; Willems, L.; Uzunov, M.; Ifrah, N.; Dreyfus, F.; Lacombe, C.; Mayeux, P.; Bouscary, D. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia Blood 2009, 114, 1618-1627
18. Channavajhala, P.; Seldin, D. C. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis Oncogene 2002, 21 (34) 5280-5288
19. Ahmad, K. A.; Wang, G.; Unger, G.; Slaton, J.; Ahmed, K. Protein kinase CK2-a key suppressor of apoptosis Adv. Enzyme Regul. 2008, 48, 179-187
20. Bliesath, J.; Huser, N.; Omori, M.; Bunag, D.; Proffitt, C.; Streiner, N.; Ho, C.; Siddiqui-Jain, A.; O'Brien, S. E.; Lim, J. K.; Ryckman, D. M.; Anderes, K.; Rice, W. G.; Drygin, D. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells Cancer Lett. 2012, 322, 113-118
21. Romieu-Mourez, R.; Landesman-Bollag, E.; Seldin, D. C.; Traish, A. M.; Mercurio, F.; Sonenshein, G. E. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer Cancer Res. 2001, 61 (9) 3810-3818
22. Chen, J.; Kobayashi, M.; Darmanin, S.; Qiao, Y.; Gully, C.; Zhao, R.; Yeung, S. C.; Lee, M. H. Pim-1 plays a pivotal role in hypoxia-induced chemoresistance Oncogene 2009, 28, 2581-2592
23. Mottet, D.; Ruys, S. P.; Demazy, C.; Raes, M.; Michiels, C. Role for casein kinase 2 in the regulation of HIF-1 activity Int. J. Cancer 2005, 117 (5) 764-774
24. Di Maira, G.; Brustolon, F.; Bertacchini, J.; Tosoni, K.; Marmiroli, S.; Pinna, L. A.; Ruzzene, M. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level Oncogene 2007, 26, 6915-6926
25. Xie, Y.; Xu, K.; Linn, D. E.; Yang, X.; Guo, Z.; Shimelis, H.; Nakanishi, T.; Ross, D. D.; Chen, H.; Fazli, L.; Gleave, M. E.; Qiu, Y. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells J. Biol. Chem. 2008, 283, 3349-3356
26. Zheng, Y.; Qin, H.; Frank, S. J.; Deng, L.; Litchfield, D. W.; Tefferi, A.; Pardanani, A.; Lin, F. T.; Li, J.; Sha, B.; Benveniste, E. N. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway Blood 2011, 118, 156-166
27. Miyata, Y. Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery Cell. Mol. Life Sci. 2009, 66 (11-12) 1840-1849
28. Jacobs, M. D.; Black, J.; Futer, O.; Swenson, L.; Hare, B.; Fleming, M.; Saxena, K. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002 J. Biol. Chem. 2005, 280, 13728-13734
29. Kumar, A.; Mandiyan, V.; Suzuki, Y.; Zhang, C.; Rice, J.; Tsai, J.; Artis, D. R.; Ibrahim, P.; Bremer, R. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma J. Mol. Biol. 2005, 348, 183-193
30. Qian, K. C.; Studts, J.; Wang, L.; Barringer, K.; Kronkaitis, A.; Peng, C.; Baptiste, A.; LaFrance, R.; Mische, S.; Farmer, B. Expression, purification, crystallization and preliminary crystallographic analysis of human Pim-1 kinase Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun. 2005, 61, 96-99
31. Qian, K. C.; Wang, L.; Hickey, E. R.; Studts, J.; Barringer, K.; Peng, C.; Kronkaitis, A.; Li, J.; White, A.; Mische, S.; Farmer, B. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase J. Biol. Chem. 2005, 280, 6130-6137
32. Bullock, A. N.; Russo, S.; Amos, A.; Pagano, N.; Bregman, H.; Debreczeni, J. E.; Lee, W. H.; von Delft, F.; Meggers, E.; Knapp, S. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor PLoS One 2009, 4 (10) e7112
33. Qian, K.; Wang, L.; Cywin, C. L.; Farmer, B. T., 2nd; Hickey, E.; Homon, C.; Jakes, S.; Kashem, M. A.; Lee, G.; Leonard, S.; Li, J.; Magboo, R.; Mao, W.; Pack, E.; Peng, C.; Prokopowicz, A., 3rd; Welzel, M.; Wolak, J.; Morwick, T. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode J. Med. Chem. 2009, 52 (7) 1814-1827
34. Lopez-Ramos, M.; Prudent, R.; Moucadel, V.; Sautel, C. F.; Barette, C.; Lafanechere, L.; Mouawad, L.; Grierson, D.; Schmidt, F.; Florent, J. C.; Filippakopoulos, P.; Bullock, A. N.; Knapp, S.; Reiser, J. B.; Cochet, C. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights FASEB J. 2010, 24, 3171-3185
35. Pierre, F.; Regan, C. F.; Chevrel, M. C.; Siddiqui-Jain, A.; Macalino, D.; Streiner, N.; Drygin, D.; Haddach, M.; O'Brien, S. E.; Rice, W. G.; Ryckman, D. M. Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells Bioorg. Med. Chem. Lett. 2012, 22, 3327-3331
36. Anizon, F.; Shtil, A. A.; Danilenko, V. N.; Moreau, P. Fighting tumor cell survival: advances in the design and evaluation of Pim inhibitors Curr. Med. Chem. 2010, 17, 4114-4133
37. Morwick, T. Pim kinase inhibitors: a survey of the patent literature Expert Opin. Ther. Pat. 2010, 20 (2) 193-212
38. Tao, Z. F.; Hasvold, L. A.; Leverson, J. D.; Han, E. K.; Guan, R.; Johnson, E. F.; Stoll, V. S.; Stewart, K. D.; Stamper, G.; Soni, N.; Bouska, J. J.; Luo, Y.; Sowin, T. J.; Lin, N. H.; Giranda, V. S.; Rosenberg, S. H.; Penning, T. D. Discovery of 3 H -benzo[4,5]thieno[3,2- d ]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases J. Med. Chem. 2009, 52 (21) 6621-6636
39. Chen, L. S.; Redkar, S.; Bearss, D.; Wierda, W. G.; Gandhi, V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells Blood 2009, 114, 4150-4157
40. Mumenthaler, S. M.; Ng, P. Y.; Hodge, A.; Bearss, D.; Berk, G.; Kanekal, S.; Redkar, S.; Taverna, P.; Agus, D. B.; Jain, A. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes Mol. Cancer Ther. 2009, 8, 2882-2893
41. Pogacic, V.; Bullock, A. N.; Fedorov, O.; Filippakopoulos, P.; Gasser, C.; Biondi, A.; Meyer-Monard, S.; Knapp, S.; Schwaller, J. Structural analysis identifies imidazo[1,2- b ]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity Cancer Res. 2007, 67, 6916-6924
42. Siu, A.; Virtanen, C.; Jongstra, J. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells Oncotarget 2011, 2, 1134-1144
43. Mahalingam, D.; Espitia, C. M.; Medina, E. C.; Esquivel, J. A., 2nd; Kelly, K. R.; Bearss, D.; Choy, G.; Taverna, P.; Carew, J. S.; Giles, F. J.; Nawrocki, S. T. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma Br. J. Cancer 2011, 105, 1563-1573
44. Chen, L. S.; Redkar, S.; Taverna, P.; Cortes, J. E.; Gandhi, V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia Blood 2011, 118, 693-702
45. Hospital, M. A.; Green, A. S.; Lacombe, C.; Mayeux, P.; Bouscary, D.; Tamburini, J. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells Blood 2012, 119, 1791-1792
46. Kim, K. T.; Baird, K.; Ahn, J. Y.; Meltzer, P.; Lilly, M.; Levis, M.; Small, D. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival Blood 2005, 105, 1759-1767
47. Kim, K. T.; Levis, M.; Small, D. Constitutively activated FLT3 phosphorylates BAD partially through pim-1 Br. J. Haematol. 2006, 134, 500-509
48. Pastor, J.; Oyarzabal, J.; Saluste, G.; Alvarez, R. M.; Rivero, V.; Ramos, F.; Cendon, E.; Blanco-Aparicio, C.; Ajenjo, N.; Cebria, A.; Albarran, M. I.; Cebrian, D.; Corrionero, A.; Fominaya, J.; Montoya, G.; Mazzorana, M. Hit to lead evaluation of 1,2,3-triazolo[4,5- b ]pyridines as PIM kinase inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 1591-1597
49. Fathi, A. T.; Arowojolu, O.; Swinnen, I.; Sato, T.; Rajkhowa, T.; Small, D.; Marmsater, F.; Robinson, J. E.; Gross, S. D.; Martinson, M.; Allen, S.; Kallan, N. C.; Levis, M. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase Leuk. Res. 2012, 36, 224-231
50. Xiang, Y.; Hirth, B.; Asmussen, G.; Biemann, H. P.; Bishop, K. A.; Good, A.; Fitzgerald, M.; Gladysheva, T.; Jain, A.; Jancsics, K.; Liu, J.; Metz, M.; Papoulis, A.; Skerlj, R.; Stepp, J. D.; Wei, R. R. The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 3050-3056
51. Huber, K.; Brault, L.; Fedorov, O.; Gasser, C.; Filippakopoulos, P.; Bullock, A. N.; Fabbro, D.; Trappe, J.; Schwaller, J.; Knapp, S.; Bracher, F. 7,8-Dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes J. Med. Chem. 2012, 55 (1) 403-413
52. Akue-Gedu, R.; Letribot, B.; Saugues, E.; Debiton, E.; Anizon, F.; Moreau, P. Kinase inhibitory potencies and in vitro antiproliferative activities of N-10 substituted pyrrolo[2,3- a ]carbazole derivatives Bioorg. Med. Chem. Lett. 2012, 22, 3807-3809
53. Nakano, H.; Saito, N.; Parker, L.; Tada, Y.; Abe, M.; Tsuganezawa, K.; Yokoyama, S.; Tanaka, A.; Kojima, H.; Okabe, T.; Nagano, T. Rational evolution of a novel type of potent and selective proviral integration site in moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound J. Med. Chem. 2012, 55 (11) 5151-5164
54. Tsuhako, A. L.; Brown, D. S.; Koltun, E. S.; Aay, N.; Arcalas, A.; Chan, V.; Du, H.; Engst, S.; Franzini, M.; Galan, A.; Huang, P.; Johnston, S.; Kane, B.; Kim, M. H.; Laird, A. D.; Lin, R.; Mock, L.; Ngan, I.; Pack, M.; Stott, G.; Stout, T. J.; Yu, P.; Zaharia, C.; Zhang, W.; Zhou, P.; Nuss, J. M.; Kearney, P. C.; Xu, W. The design, synthesis, and biological evaluation of PIM kinase inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 3732-3738
55. Nishiguchi, G. A.; Atallah, G.; Bellamacina, C.; Burger, M. T.; Ding, Y.; Feucht, P. H.; Garcia, P. D.; Han, W.; Klivansky, L.; Lindvall, M. Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases Bioorg. Med. Chem. Lett. 2011, 21, 6366-6369
56. Haddach, M.; Michaux, J.; Schwaebe, M. K.; Pierre, F.; O'Brien, S. E.; Borsan, C.; Tran, J.; Rafaelle, N.; Ravula, S.; Drygin, D.; Siddiqui-Jain, A.; Darjania, L.; Stansfield, R.; Proffitt, C.; Macalino, D.; Streiner, N.; Bliesath, J.; Omori, M.; Whitten, J. P.; Anderes, K.; Rice, W. G.; Ryckman, D. M. Discovery of CX-6258. A potent, selective, and orally efficacious pan-Pim kinases inhibitor ACS Med. Chem. Lett. 2012, 3, 135-139
57. Pierre, F.; Stefan, E.; Nedellec, A. S.; Chevrel, M. C.; Regan, C. F.; Siddiqui-Jain, A.; Macalino, D.; Streiner, N.; Drygin, D.; Haddach, M.; O'Brien, S. E.; Anderes, K.; Ryckman, D. M. 7-(4 H -1,2,4-Triazol-3-yl)benzo[ c ][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity Bioorg. Med. Chem. Lett. 2011, 21, 6687-6692
58. Gross, S. D.; Robinson, J. E.; Allen, S.; Cox, A.; DeWolf, W. E.; Galbraith, S.; Lee, P.; Lemieux, C.; Lyssikatos, J. P.; Marmsater, F.; Martinson, M.; Munson, M. C.; Wallace, R. D.; Woessner, R.; Zuzack, J.; Winkler, J.; Koch, K. Characterization of the Effects of Pim Kinase Inhibition on Multiple Oncogene-Driven Cell Lines. Presented at the 50th Annual Meeting of the American Society of Hematology, San Francisco, CA, 2008.
59. Ebens, A. J.; Berry, L.; Chen, Y.-H.; Deshumkh, G.; Drummond, G.; Du, C.; Eby, M.; Fitzgerald, K.; Friedman, L. S.; Gould, S. E.; Kenny, J. R.; Maecker, H.; Moffat, J.; Moskalenko, M.; Pacheco, P.; Saadat, A.; Slaga, D.; Sun, L.; Wang, G.; Yang, Y.; Munugalavdla, V. A Selective PIM Kinase Inhibitor Is Highly Active in Multiple Myeloma: The Biology of Single Agent and PI3K/AKT/mTOR Combination Activity. Presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology, San Diego, CA, 2011.
60. Czardybon, W.; Windak, R.; Krawczynska, K.; Zarebski, A.; Dolata, I.; Salwinska, M.; Surawska, M.; Sabiniarz, A.; Szamborska-Gbur, A.; Prymula, K.; Milik, M.; Kosowska-Wardega, A.; Trebacz, E.; Rsymski, T.; Kowalczyk, P.; Brzozka, K. Development of Selective Pim Kinase Inhibitors for Cancer Treatment. Presented at the 2012 Annual Meeting of the American Association for Cancer Research, Chicago, IL, 2012.
61. Keeton, E.; McEachem, K.; Alimzhanov, M.; Wang, S.; Cao, Y.; Bao, L.; Palakurthi, S.; Grondine, M.; Chen, Y.; Dillman, K.; Chinnappan, D.; Shen, M.; Dakin, L.; Zheng, X.; Lamb, M.; Wu, A.; Chen, H.; Lyne, P.; Huszar, D. Efficacy and Biomarker Modulation by AZD1208, a Novel, Potent and Selective Pan-Pim Kinase Inhibitor, in Models of Acute Meloid Leukemia. Presented at the 2012 Annual Meeting of the American Association for Cancer Research, Chicaogo, IL, 2012.
62. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem. J. 2000, 351 (Part 1) 95-105
63. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4 H -1-benzopyran-4-one (LY294002) J. Biol. Chem. 1994, 269 (7) 5241-5248
64. Cheng, H.; Force, T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog. Cardiovasc. Dis. 2010, 53, 114-120
65. Hasinoff, B. B.; Patel, D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro Toxicol. Appl. Pharmacol. 2010, 249, 132-139
66. Fischer, K. M.; Cottage, C. T.; Wu, W.; Din, S.; Gude, N. A.; Avitabile, D.; Quijada, P.; Collins, B. L.; Fransioli, J.; Sussman, M. A. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase Circulation 2009, 120, 2077-2087
67. Liu, D.; He, M.; Yi, B.; Guo, W. H.; Que, A. L.; Zhang, J. X. Pim-3 protects against cardiomyocyte apoptosis in anoxia/reoxygenation injury via p38-mediated signal pathway Int. J. Biochem. Cell Biol. 2009, 41, 2315-2322
68. Zhao, L.; Wang, Y.; Min, X.; Yang, H.; Zhang, P.; Zeng, Q. Ischemia-reperfusion injury up-regulates Pim-3 gene expression in myocardial tissue J. Huazhong Univ. Sci. Technol., Med. Sci. 2010, 30 (6) 704-708
69. Kim, S. O.; Baines, C. P.; Critz, S. D.; Pelech, S. L.; Katz, S.; Downey, J. M.; Cohen, M. V. Ischemia induced activation of heat shock protein 27 kinases and casein kinase 2 in the preconditioned rabbit heart Biochem. Cell Biol. 1999, 77 (6) 559-567
70. Sussman, M. A.; Volkers, M.; Fischer, K.; Bailey, B.; Cottage, C. T.; Din, S.; Gude, N.; Avitabile, D.; Alvarez, R.; Sundararaman, B.; Quijada, P.; Mason, M.; Konstandin, M. H.; Malhowski, A.; Cheng, Z.; Khan, M.; McGregor, M. Myocardial AKT: the omnipresent nexus Physiol. Rev. 2011, 91, 1023-1070